Sonexa 4 (Dexamethasone) tablet contains 4 mg of Dexamethasone which is a corticosteroid.
Dexamethasone exhibits both anti-inflammatory and immune suppressant properties. It prevents the functions of phospholipase A2 and thereby causes anti-inflammatory action. It also interferes in the function of mediators of inflammatory response and causes suppression of immune responses. Sonexa 4 tablet is indicated for the pretreatment of chemotherapy to reduce delayed inflammation and side effects associated with chemotherapy.
Each film coated tablet contains Dexamethasone USP 4 mg.
Sonexa 4 tablet is indicated for the pretreatment of chemotherapy to reduce delayed inflammation and side effects associated with chemotherapy. Sonexa 4 tablet is indicated for the prevention of nausea and vomiting associated with Cisplatin-based highly emetogenic chemotherapy, moderately emetogenic chemotherapy and combinations of Anthracycline and Cyclophosphamide.
The recommended dosage of Sonexa 4 tablet is as following table for the prevention of delayed inflammation and side effects associated with chemotherapy:
Cisplatin-based highly emetogenic cancer chemotherapy-
| Day 1 | Day 2 | Day 3 | Day 4 | |
| Dexamethasone | 20 mg; 30 min prior to chemotherapy. | 8 mg twice daily |
8 mg twice daily |
8 mg twice daily |
| Rolapitant | 180 mg; Approximately 1-2 hours prior to chemotherapy. | None | ||
| 5-HT3 receptor antagonist. |
See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. |
None | ||
Moderately emetogenic cancer chemotherapy and combinations of Anthracycline and Cyclophosphamide-
| Day 1 | Day 2 | Day 3 | Day 4 | |
| Dexamethasone | 20 mg; 30 min prior to chemotherapy. | None | ||
| Rolapitant | 180 mg; Approximately 1-2 hours prior to chemotherapy. | None | ||
| 5-HT3 receptor antagonist. |
See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. | |||
Dexamethasone is contraindicated in patients who are hypersensitive to any components of this product. It is also contraindicated in patients with systemic infections unless specific anti-infective therapy given or live virus immunization.
Caution is necessary in patients with the following conditions: Hypertension, hypothyroidism, recent congestive heart or liver failure, renal insufficiency, diabetes mellitus, osteoporosis, glaucoma, steroid induced psychoses, epilepsy and seizure disorder, peptic ulceration, previous steroid myopathy and tuberculosis. Caution is also necessary for patients with thromboembolic disorders, Duchenne's muscular dystrophy, Cushing's disease and patients with myasthenia gravis receiving anticholinesterase therapy.
Gastro-intestinal: Dyspepsia, nausea, peptic ulceration, abdominal distension, abdominal pain, diarrhoea, oesophageal ulceration, oesophageal candidiasis and acute pancreatitis. Musculoskeletal: Proximal myopathy and osteoporosis. Endocrine: Suppression of the hypothalamo-pituitary adrenal axis; growth suppression in infancy, childhood and adolescence; menstrual irregularity; amenorrhoea and cushingoid faces. Nervous system: Depression, insomnia and dizziness. Eye disorders: Increased intra-ocular pressure and glaucoma. Immunosuppressive effects: Increased susceptibility to and severity of infections.
CYP3A4 inducers: Phenobarbital, phenytoin, rifampicin, rifabutin, carbamazepine, primidone and aminoglutethimide may reduce the efficacy of dexamethasone. CYP3A4 inhibitors: Ketoconazole, ciclosporin or ritonavir may decrease dexamethasone clearance. Dose adjustment may be considered for any concurrent anti-diabetic therapy as conticosteroids may increase blood glucose level. Concomitant administration of NSAIDs with corticosteroids may increase the risk of GI ulceration. Concurrent use of antacids may decrease the absorption of corticosteroids. Response to anticoagulants may be reduced or less often enhanced by corticosteroids. The risk of hypokalaemia may be increased with amphoteracin. Eestrogens may potentiate the effects of glucocorticoids. The growth promoting effects of somatotropin may be inhibited.
PREGNANCY AND LACTATION:
Dexamethasone readily crosses the placenta and it may excrete into breast milk. Dexamethasone should only be prescribed when the benefits to the mother and child outweigh the risks.
PEDIATRIC AND GERIATRIC USE:
Long-term use should be avoided as it causes growth retardation in infancy, childhood and adolescence. Elderly patients are more susceptible to the side effects; therefore long-term use should be planned with caution.
HEPATIC AND RENAL INSUFFICIENCY:
Therapy with Dexamethasone should be used with great caution in these patients.
Storage:
Store below 300C, keep in dry place & protect from light. keep out of the reach of children.
Presentation:
Each box contains 20 tablets in blister pack.
FR
DE
